InforMed breaks down the head-to-head question between Novo's CagriSema and tirzepatide using the 84-week trial results.
Recap by typeshit. Full story at InforMed.
Researchers found the peptide they built as a treatment already circulates in human blood, at lower levels in people with cognitive impairment.
Topol points to work suggesting the body's own GLP-1 family peptides help reduce inflammation in the gut. Details are thin, so tap through for the study.
Medscape explores whether GLP-1 medicines might help keep people with schizophrenia out of the hospital. Tap through for the evidence behind the idea.
The weight loss drug class started with a lizard. A short local feature looks at how the Gila monster led researchers to GLP-1 medicines.
Dr. Beverly Tchang shares a finding from the American College of Gastroenterology meeting: GLP-1 use was linked to a 67.5% lower colorectal cancer risk.
After advisers backed adding BPC-157, TB-500, KPV and others to the 503A bulks list, pharmacists are waiting on the FDA's final decision.
Loading…